Testing considerations for phosphatidylinositol‐3‐kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer

by Deborah L. Toppmeyer, Michael F. Press
Published 2020-09-01

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

by Mridula A. George, Sadaf Qureshi, Coral Omene, Deborah L. Toppmeyer, Shridar Ganesan
Published 2021-07-01

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer

by Elan Gorshein, Kant Matsuda, Gregory Riedlinger, Levi Sokol, Lorna Rodriguez-Rodriguez, Firas Eladoumikdachi, Miral Grandhi, Shridar Ganesan, Deborah L. Toppmeyer, Lindsay Potdevin, Kathleen Toomey, Kim M. Hirshfield, Nancy Chan
Published 2021-06-01

Metabotropic glutamate receptor 1 expression and its polymorphic variants associate with breast cancer phenotypes.

by Madhura S Mehta, Sonia C Dolfi, Roman Bronfenbrener, Erhan Bilal, Chunxia Chen, Dirk Moore, Yong Lin, Hussein Rahim, Seena Aisner, Romona D Kersellius, Jessica Teh, Suzie Chen, Deborah L Toppmeyer, Dan J Medina, Shridar Ganesan, Alexei Vazquez, Kim M Hirshfield
Published 2013-01-01